Royal Philips: Philips and Imricor launch cardiac interventional MR lab solution, expanding longstanding collaboration
Royal Philips and Imricor Medical Systems launched a cardiac interventional MR lab solution, combining Philips' 1.5T MRI platform with Imricor's MR-compatible systems. The solution aims to enhance cardiac intervention procedures by providing detailed tissue visualization without radiation. It is commercially available in CE-marked markets and some U.S. configurations, with further U.S. availability pending regulatory clearances.
How this was made
The 30-second read
Why it matters
The announcement positions an iMR lab as a turnkey, radiation-free alternative to X-ray fluoroscopy for catheter ablation, potentially improving visualization and procedural guidance. However, the article does not provide financial metrics or quantified demand, so trading impact is likely sentiment-driven rather than fundamentals-driven immediately.
Market read
A commercial iMR lab solution launch can influence expectations for MR-guided cardiac procedure adoption, but the lack of quantified commercial uptake limits immediate trading decisiveness.
What to watch
Adoption depends on clinical workflow integration, training, and regulatory clearance for additional U.S. configurations, which the article flags as pending for some products.
Background
Philips and Imricor have an existing collaboration aimed at MR-guided cardiac interventions; this announcement formalizes a first commercially available iMR lab configuration for Philips 1.5T systems.
Ticker impact
Philips announced a new Interventional MR lab solution combining its 1.5T MRI platform with Imricor’s iMR systems and consumables.
Mild positive bias for PHG on adoption expectations, with limited immediate earnings sensitivity.
The article is a commercial product launch with CE-marked availability and some U.S. configurations, but it provides no revenue, pricing, or order volume.
Market effects
Highlights competitive push to move MRI from diagnosis into interventional workflows, potentially increasing attention on MR-guided electrophysiology and radiation-free procedures.
Near-term sales momentum may be concentrated in Europe where CE-marked configurations are available immediately.
If adoption scales, it could broaden global demand for 1.5T MRI platforms and MR-compatible interventional consumables.
Counterpoint
Without disclosed order volumes, pricing, or reimbursement progress, the launch may not translate into material near-term revenue for either company.
Key entities
- companyRoyal Philips
Announced a new Interventional MR lab solution built on its 1.5T MRI platform and Cardiac MR Suite.
- companyImricor Medical Systems
Provides MR-compatible iMR systems and consumables (e.g., NorthStar iMR mapping and guidance, EP Recorder/Stimulator, Vision-MR catheters) bundled into the Philips solution.
- eventESC Congress 2026
The iMR lab solution will be showcased in Munich at ESC Congress 2026.
